inclusion criteria: subjects in this study must meet all of the following criteria: 1. male or female patients with hematological malignancies who are in stable condition or with bone marrow failure disorders and aged from 1 to 75 years old on the day of enrollment; 2. on the day of enrollment, the subject was judged to be positive for covid-19 nucleic acid/antigen for more than 10 days without turning negative or had turned negative but recovered positive again after 10 days; 3. on the day of enrollment, patients who have received car t-cell therapy, corticosteroids for a long time or other immuno-suppressive drugs, with the proportion of peripheral blood b cells is less than 2%; 4. subjects (men and women with childbearing potential) and their sexual partners voluntarily take effective contraceptive measures from 4 weeks before screening to 3 months after the last dose of the test drug, and have no plan to donate sperm or eggs; 5. subjects voluntarily participate in the trial and sign the informed consent form before the study begins.

inclusion criteria: subjects in this study must meet all of the following criteria: 1. male or female patients with hematological malignancies who are in stable condition or with bone marrow failure disorders and aged from 1 to 75 years old on the day of enrollment; 2. on the day of enrollment, the subject was judged to be positive for covid-19 nucleic acid/antigen for more than 10 days without turning negative or had turned negative but recovered positive again after 10 days; 3. on the day of enrollment, patients who have received car t-cell therapy, corticosteroids for a long time or other immuno-suppressive drugs, with the proportion of peripheral blood b cells is less than 2%; 4. subjects (men and women with childbearing potential) and their sexual partners voluntarily take effective contraceptive measures from 4 weeks before screening to 3 months after the last dose of the test drug, and have no plan to donate sperm or eggs; 5. subjects voluntarily participate in the trial and sign the informed consent form before the study begins.

inclusion criteria: subjects in this study must meet all of the following criteria: male or female patients with hematological malignancies who are in stable condition or with bone marrow failure disorders and aged from 1 to 75 years old on the day of enrollment; on the day of enrollment, the subject was judged to be positive for covid-19 nucleic acid/antigen for more than 10 days without turning negative or had turned negative but recovered positive again after 10 days; on the day of enrollment, patients who have received car t-cell therapy, corticosteroids for a long time or other immuno-suppressive drugs, with the proportion of peripheral blood b cells is less than 2%; subjects (men and women with childbearing potential) and their sexual partners voluntarily take effective contraceptive measures from 4 weeks before screening to 3 months after the last dose of the test drug, and have no plan to donate sperm or eggs; subjects voluntarily participate in the trial and sign the informed consent form before the study begins.

inclusion criteria: subjects in this study must meet all of the following criteria: male or female patients with hematological malignancies who are in stable condition or with bone marrow failure disorders and aged from 1 to 75 years old on the day of enrollment; on the day of enrollment, the subject was judged to be positive for covid-19 nucleic acid/antigen for more than 10 days without turning negative or had turned negative but recovered positive again after 10 days; on the day of enrollment, patients who have received car t-cell therapy, corticosteroids for a long time or other immuno-suppressive drugs, with the proportion of peripheral blood b cells is less than 2%; subjects (men and women with childbearing potential) and their sexual partners voluntarily take effective contraceptive measures from 4 weeks before screening to 3 months after the last dose of the test drug, and have no plan to donate sperm or eggs; subjects voluntarily participate in the trial and sign the informed consent form before the study begins.

inclusion criteria: subjects in this study must meet all of the following criteria: male or female patients with hematological malignancies who are in stable condition and aged from 1 to 75 years old on the day of enrollment; on the day of enrollment, the subject was judged to be positive for covid-19 nucleic acid/antigen for more than 10 days without turning negative or had turned negative but recovered positive again after 10 days; on the day of enrollment, the proportion of peripheral blood b cells is less than 2%; subjects (men and women with childbearing potential) and their sexual partners voluntarily take effective contraceptive measures from 4 weeks before screening to 3 months after the last dose of the test drug, and have no plan to donate sperm or eggs; subjects voluntarily participate in the trial and sign the informed consent form before the study begins.

inclusion criteria: subjects in this study must meet all of the following criteria: male or female patients with hematological malignancies who are in stable condition and aged from 1 to 75 years old on the day of enrollment; on the day of enrollment, the subject was judged to be positive for covid-19 nucleic acid/antigen for more than 10 days without turning negative or had turned negative but recovered positive again after 10 days; on the day of enrollment, the proportion of peripheral blood b cells is less than 2%; subjects (men and women with childbearing potential) and their sexual partners voluntarily take effective contraceptive measures from 4 weeks before screening to 3 months after the last dose of the test drug, and have no plan to donate sperm or eggs; subjects voluntarily participate in the trial and sign the informed consent form before the study begins.

inclusion criteria: subjects in this study must meet all of the following criteria: male or female patients with hematological malignancies who are in stable condition and aged from 1 to 75 years old on the day of enrollment; on the day of enrollment, the subject was judged to be positive for covid-19 nucleic acid for more than 10 days without turning negative or had turned negative but recovered positive again after 10 days; on the day of enrollment, the proportion of peripheral blood b cells is less than 2%; subjects (men and women with childbearing potential) and their sexual partners voluntarily take effective contraceptive measures from 4 weeks before screening to 3 months after the last dose of the test drug, and have no plan to donate sperm or eggs; subjects voluntarily participate in the trial and sign the informed consent form before the study begins.

inclusion criteria: subjects in this study must meet all of the following criteria: male or female patients with hematological malignancies who are in stable condition and aged from 1 to 75 years old on the day of enrollment; on the day of enrollment, the subject was judged to be positive for covid-19 nucleic acid for more than 10 days without turning negative or had turned negative but recovered positive again after 10 days; on the day of enrollment, the proportion of peripheral blood b cells is less than 2%; subjects (men and women with childbearing potential) and their sexual partners voluntarily take effective contraceptive measures from 4 weeks before screening to 3 months after the last dose of the test drug, and have no plan to donate sperm or eggs; subjects voluntarily participate in the trial and sign the informed consent form before the study begins.